Besifovir Dipivoxil maleate
Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies[2]
For research use only. We do not sell to patients.
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1039623-01-2
-
Molecular Weight 643.58
-
Formula C26H38N5O12P
-
SMILES
NC1=NC=C2N=CN(CC3(OCP(OCOC(C(C)(C)C)=O)(OCOC(C(C)(C)C)=O)=O)CC3)C2=N1.O=C(O)/C=C\C(O)=O
-
Synonyms
LB80380 maleate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Yuen MF, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83. [Content Brief]
[2]. Lai CL, et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014 Jun;63(6):996-1004. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)